What Integra Therapeutics does

Integra Therapeutics S.L. is a Barcelona, Spain-based preclinical biotechnology company developing the FiCAT (Find-Cut-And-Transfer) gene writing platform for cell and gene therapies. FiCAT combines the precision of CRISPR-Cas for targeted genomic site identification with an engineered PiggyBac transposase that performs controlled, non-viral DNA insertion, enabling precise, stable integration of both small and large payloads into predetermined genomic loci. AI-powered computational bioprospecting across more than 31,000 eukaryotic genomes is used to design hyperactive synthetic transposases, with results peer-reviewed in Nature Communications (2021) and Nature Biotechnology (2025). The platform supports ex vivo CAR-T manufacturing with demonstrated single-step multiplexing of up to four therapeutic genes plus removal of one unwanted gene, and in vivo liver-directed applications delivered via lipid nanoparticle (LNP) pre-loading.

The company is pre-revenue and at preclinical stage, pursuing a partnership-driven go-to-market model targeting pharmaceutical and biotechnology companies developing CAR-T, autoimmune and rare genetic disease therapies. Revenue is expected to materialize through licensing of the FiCAT platform and co-development agreements, generating upfront fees, milestone payments and royalties on approved products. Distribution is enterprise-direct via licensing and co-development partnerships; marketing relies on organic social (LinkedIn, X, YouTube), peer-reviewed publications and conference presentations (e.g., ASGCT). Customer segments are horizontal across pharma and biotech business units developing oncological, autoimmune and genetic disease therapies, with the pain point being limitations of viral vectors such as random integration, size constraints and multi-step manufacturing.

The company was founded in 2020–2021 and is incorporated in Spain as INTEGRA THERAPEUTICS S.L., headquartered in Esplugues de Llobregat, Barcelona. It has raised a €4.5M seed (December 2021, Advent France Biotechnology, Invivo Capital, Takeda Ventures), completed the seed at €6M (March 2022, Columbus Venture Partners), received EIC Accelerator grant funding (July 2024), and closed a €10.7M pre-Series A (September 2025, EIC Fund, CDTI Innvierte and existing investors). Leadership includes co-founder and CEO Avencia Sánchez-Mejías, PhD, co-founder and Scientific Head Marc Güell, VP Translational Development Margot Pont, PhD, and Independent Chairman Miles Gerson (appointed December 2025, formerly Global Head of Takeda Ventures).

Name

Integra Therapeutics

Legal name

INTEGRA THERAPEUTICS S.L.

Website

https://integra-tx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Integra Therapeutics is a Barcelona-based preclinical biotechnology company developing the FiCAT gene writing platform, which combines CRISPR-Cas targeting with engineered PiggyBac transposase, for ex vivo CAR-T cell therapies and in vivo gene therapies targeting oncology, autoimmune and genetic diseases.

Ownership category

akta.pro rank

Product category

Gene Editing Platform Technology

akta.pro primary industry

Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)

akta.pro secondary industries

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

Keywords

• Gene editing platform
• Cell therapy tools
• Gene writing technology
• CAR-T therapy development
• CRISPR transposase platform

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Platform Licensing: Pre-revenue company in preclinical development stage, expected to generate revenue through licensing its FiCAT platform technology to pharmaceutical and biotech companies for development of cell and gene therapies.
2. Co-development Partnerships: Strategic partnerships with pharmaceutical companies for co-development of therapies using the FiCAT platform, potentially including upfront payments, milestone payments, and royalties on approved products.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Integra Therapeutics develops the FiCAT (Find-Cut-And-Transfer) gene writing platform, which combines CRISPR-Cas precision targeting with an engineered PiggyBac transposase to enable precise, efficient, and stable insertion of small and large DNA payloads into genomes. The platform is applied to next-generation CAR-T cell therapy manufacturing and liver-directed in vivo gene therapy for oncological, autoimmune, and genetic diseases.

Product overview

Integra Therapeutics is a Barcelona-based biotechnology company developing the FiCAT (Find-Cut-And-Transfer) gene writing platform as its core technology. The FiCAT platform combines CRISPR-Cas precision targeting with an engineered PiggyBac transposase for gene insertion, enabling safer and more effective cell and gene therapies. The company is advancing applications in ex vivo CAR-T cell therapy and in vivo liver-directed gene therapy for treating oncological, autoimmune, and genetic diseases. The platform can be delivered in a viral-free manner via LNP pre-loading.

Differentiator

Problem solved

Functional benefit

Brands

• FiCAT: Find-Cut-And-Transfer gene writing platform that combines CRISPR-Cas precision with PiggyBac transposase for efficient, stable insertion of DNA fragments into genomes for ex vivo and in vivo cell therapy and gene therapy applications.

Products and services

• FiCAT (Find-Cut-And-Transfer) Gene Writing Platform Next-generation gene writing platform combining CRISPR-Cas precision targeting with an engineered PiggyBac transposase to enable precise, efficient, and stable insertion of DNA fragments of varying sizes into genomes for ex vivo and in vivo cell and gene therapy applications. Licensed to pharmaceutical and biotech partners for therapeutic development.
• FiCAT CAR-T Cell Therapy Development Next-generation CAR-T cell therapy development using the FiCAT platform, demonstrating single-step multiplex gene insertion and deactivation capability for cancer treatment, with head-to-head preclinical comparisons showing matched or superior performance versus lentiviral vectors.
• FiCAT Liver-Directed In Vivo Gene Therapy Liver-directed in vivo gene therapy applications using the FiCAT platform, delivered in a viral-free manner via lipid nanoparticle (LNP) pre-loading, with demonstrated efficiency in liver tissues for treatment of genetic diseases.

Quantifiable outcome

• Matched or outperformed lentiviral vectors (current gold standard for CAR-T) in cell viability, tumor-killing ability, and genotoxicity in head-to-head preclinical comparisons
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Beam Therapeutics: Beam Therapeutics is a direct peer operating in the precision gene-editing space (base editing) with in vivo and ex vivo programs targeting oncology and genetic diseases—an adjacent gene-editing modality that competes for the same partnership and licensing dollars as Integra.
• Prime Medicine: Prime Medicine develops prime editing, a next-generation gene-editing modality that competes with FiCAT for in vivo and ex vivo therapeutic applications, particularly where precise insertions are required.
• Editas Medicine: Editas Medicine is a direct peer developing CRISPR-based gene-editing medicines, including ex vivo cell therapies and in vivo editing approaches, sharing Integra's core technology category and customer base of pharma partners.
• CRISPR Therapeutics: CRISPR Therapeutics is a direct peer commercialising CRISPR/Cas-based ex vivo gene-edited cell therapies (notably CASGEVY) and in vivo gene-editing programs. It is the most clinically advanced competitor in the genome editing space where Integra's FiCAT platform operates.
• Caribou Biosciences: Caribou Biosciences is a direct peer applying CRISPR-based gene editing to allogeneic CAR-T cell therapy manufacturing—sharing Integra's ex vivo CAR-T gene-editing focus and competing for similar pharma partnerships.
• Cellectis: Cellectis is a direct peer that develops gene-editing platforms (TALEN-based) for CAR-T manufacturing and therapeutic applications, directly overlapping with Integra's gene-editing approach to CAR-T cell engineering.
• Intellia Therapeutics: Intellia Therapeutics develops both ex vivo and in vivo CRISPR-based gene-editing therapies, directly overlapping with Integra's ex vivo CAR-T and in vivo liver-directed gene-therapy programs and serving similar patient populations.
• Tessera Therapeutics: Tessera Therapeutics is a direct peer pursuing 'gene writing' technology to make precise insertions into the genome, sharing Integra's fundamental approach of combining target-finding with a programmable insertion mechanism for therapeutic applications.

Emerging players

• Vor Biopharma: Vor Biopharma is an emerging player developing genome-engineered hematopoietic stem cell therapies for oncology, sharing Integra's gene-editing/cell-therapy platform technology category though focused on a narrower indication set.
• Excision BioTherapeutics: Excision BioTherapeutics is an emerging player using CRISPR-based gene editing for infectious and inherited diseases, sharing Integra's in vivo gene-editing methodology though targeting different therapeutic indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Integra_Tx
• YouTubeyoutube.com/channel/UCEXbkV0h6lVWTISeY2XtnCQ
• LinkedInlinkedin.com/company/integra-therapeutics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integra Therapeutics